Taysha completes dosing in REVEAL pivotal trial for TSHA-102 Rett syndrome therapy

Taysha Gene Therapies completed enrollment of 17 patients in its REVEAL pivotal trial for TSHA-102, with 100% of Phase 1/2 Part A patients achieving developmental milestones and no serious adverse events reported. The company expects topline interim data and FDA feedback on BLA submission pathway in H1 2027, potentially supporting accelerated approval for this gene therapy in a rare CNS disorder.